Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release

Authors:

Abstract
Significance: The main goal in the emerging field of cancer nanomedicine is to generate, standardize, and produce multifunctional carriers designed to improve the response of drugs against tumors. Here we report the design, development, and preclinical validation of a ligand-directed bioinorganic platform that integrates tumor targeting, receptor-mediated cell internalization, photon-to-heat conversion, and drug delivery. This enabling hydrogel-based technology can accommodate a broad variety of ligands, nanoparticles, and payloads. We show experimental proof-of-concept in mouse models of breast and prostate cancer with molecular imaging and marked reduction of tumor growth. However, with future proof that this technology is translatable, medical applications beyond cancer may also be leveraged.
Funding Information
  • Japan Society for the Promotion of Science (Fellowship to H.H.)
  • National Science Foundation (DMS-1562068 to V.C.)
  • NIH (1U54CA149196 and 1U54CA143907 to V.C.)
  • KAU (54-130-35-HiCi to V.C.)
  • Lumphoma Leukemia Society (7010-14 SCOR to C.J.B.)
  • NIH (U01 CA151792-01 to C.J.B.)
  • NIH (R01U54CA143837 to V.C., W.A., and R.P.)
  • NIH (1U54CA151668 yo V.C., W.A., and R.P.)
  • NIH (P50 CA140388 to W.A. and R.P.)
  • Oncothyreon (to C.J.B.)
  • Gillson-Longenbaugh Foundation and the Prostate Cancer Foundation (to W.A. and R.P.)

This publication has 36 references indexed in Scilit: